Exited portfolio company SoniVie, acquired by Boston Scientific for up to $540M.
SoniVie is a medical device company focused on developing a system for the treatment of pulmonary hypertension (PAH) using its therapeutic intravascular ultrasound (TIVUS) catheter, which selectively damages nerves associated with disease activity in the pulmonary artery
SoniVie is a medical device company focused on developing a system for the treatment of pulmonary hypertension (PAH) using its therapeutic intravascular ultrasound (TIVUS) catheter, which selectively damages nerves associated with disease activity in the pulmonary artery.